{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:56:32Z","timestamp":1788976592549,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T00:00:00Z","timestamp":1275436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine if mycophenolate mofetil (MMF) diminishes skin and muscle disease activity in children with juvenile dermatomyositis (DM), thereby permitting a decrease in corticosteroid dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective data review for 50 children with juvenile DM (mean \u00b1 SD age 12.2 \u00b1 5.0 years) who had received MMF for 12 months identified the following characteristics: 38 (76%) were girls, 39 (78%) were white, 10 (20%) were Hispanic, and 1 (2%) was African American. The MMF dose and frequency, type of infection, white blood cell (WBC) count, corticosteroid dose, and the validated disease activity score (DAS) subscores for skin (DAS\u2010S) and muscle (DAS\u2010M) were obtained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve months after the start of MMF, the mean \u00b1 SD DAS\u2010S decreased from 5.24 \u00b1 0.29 to 3.72 \u00b1 0.29 (<jats:italic>P<\/jats:italic> = 0.001), and the mean \u00b1 SD DAS\u2010M decreased from 2.44 \u00b1 0.39 to 1.17 \u00b1 0.28 (<jats:italic>P<\/jats:italic> = 0.002). The mean \u00b1 SD prednisone dosage decreased from 0.39 \u00b1 0.06 to 0.23 \u00b1 0.02 mg\/kg\/day (<jats:italic>P<\/jats:italic> = 0.0001), with resumption of linear growth (<jats:italic>P<\/jats:italic> = 0.008). The WBC\/lymphocyte count was unchanged over the 12 months on MMF. The infection rate was assessed in a subset of 26 children with juvenile DM who were observed for 12 months before the start of MMF and then compared with the ensuing 12 months of MMF therapy. There was no significant difference between the pretreatment period and the first 6 months of MMF therapy (<jats:italic>P<\/jats:italic> = 0.44), but the infection rate decreased in months 7\u201312 (<jats:italic>P<\/jats:italic> = 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MMF appears to be worthy of consideration as an additional therapeutic modality for treatment of children with juvenile DM. These data suggest that the use of MMF decreases skin and muscle disease activity and is steroid sparing. MMF appears to be well tolerated, but patients should be monitored for infection.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.20269","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T13:57:04Z","timestamp":1275487024000},"page":"1446-1451","source":"Crossref","is-referenced-by-count":80,"title":["Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis"],"prefix":"10.1002","volume":"62","author":[{"given":"Kelly A.","family":"Rouster\u2010Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Pachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11122"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-196607000-00001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23299"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-9-43"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.8.4154"},{"key":"e_1_2_6_8_2","first-page":"BR191","article-title":"cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies","volume":"10","author":"Zhou X","year":"2004","journal-title":"Med Sci Monit"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2119\/2006-00085.Baechler"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22928"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.05.011"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24555"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0337679100"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60955-1"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308098631"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308094999"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.1.65"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh499"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.07.102"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.11.001"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10924"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20179"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364408"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00467-003-1133-1","article-title":"Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children","volume":"18","author":"Filler G","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22158"},{"key":"e_1_2_6_27_2","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases","volume":"27","author":"Gelber AC","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10026"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel336"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0526-5"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4414\/smw.2009.12441","article-title":"Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies","volume":"139","author":"Bandelier C","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.04.003"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.10.032"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.043"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902913815"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22433"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000208416.32471.c0"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.08.015"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21083"},{"issue":"3","key":"e_1_2_6_40_2","first-page":"iii28","article-title":"Update on safety during pregnancy of biological agents and some immunosuppressive anti\u2010rheumatic drugs","volume":"47","author":"Ostensen M","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309347921"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.20269","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.20269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:29:17Z","timestamp":1759422557000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.20269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,2]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/acr.20269"],"URL":"https:\/\/doi.org\/10.1002\/acr.20269","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,2]]}}}